<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Disclosure Solutions PROFILE 1.3.2.0 Copyright 1995 - 2013 Thomson Reuters Accelus. All rights reserved.-->
<xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:ebs="http://ebsi.com/20130630" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="ebs-20130630.xsd" />
  <xbrli:context id="c20130101to20130630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130401to20130630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120401to20120630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20120630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20111231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsEmployeeStockOptionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsEmployeeStockOptionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsInc2006StockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ebs:EmergentBiosolutionsEmployeeStockOptionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_AwardTypeAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130630_AwardTypeAxis_EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130630_AwardTypeAxis_RestrictedStockUnitsRSUMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130630_AwardTypeAxis_RestrictedStockUnitsRSUMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130401to20130630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">ebs:OxfordEmergentTuberculosisConsortiumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">ebs:OxfordEmergentTuberculosisConsortiumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">ebs:OxfordEmergentTuberculosisConsortiumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">ebs:OxfordEmergentTuberculosisConsortiumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120401to20120630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">ebs:OxfordEmergentTuberculosisConsortiumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20120630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">ebs:OxfordEmergentTuberculosisConsortiumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_StatementEquityComponentsAxis_ParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130630_StatementEquityComponentsAxis_ParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130630_StatementEquityComponentsAxis_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130630_StatementEquityComponentsAxis_ParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130630_StatementEquityComponentsAxis_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120401to20120630_TypeOfArrangementAxis_AbbottLaboratoriesTru016Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ebs:AbbottLaboratoriesTru016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20120630_TypeOfArrangementAxis_AbbottLaboratoriesTru016Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ebs:AbbottLaboratoriesTru016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120401to20120630_TypeOfArrangementAxis_PfizerCd20Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ebs:PfizerCd20Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20120630_TypeOfArrangementAxis_PfizerCd20Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ebs:PfizerCd20Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130401to20130630_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpecialTerminationBenefitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130401to20130630_RestructuringCostAndReserveAxis_ContractTerminationMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130401to20130630_RestructuringCostAndReserveAxis_OtherRestructuringMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130401to20130630_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130630_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpecialTerminationBenefitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130630_RestructuringCostAndReserveAxis_ContractTerminationMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130630_RestructuringCostAndReserveAxis_OtherRestructuringMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130630_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpecialTerminationBenefitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_RestructuringCostAndReserveAxis_ContractTerminationMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_RestructuringCostAndReserveAxis_OtherRestructuringMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20131231_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpecialTerminationBenefitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_RestructuringCostAndReserveAxis_ContractTerminationMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_RestructuringCostAndReserveAxis_OtherRestructuringMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20121231_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130630_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpecialTerminationBenefitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130630_RestructuringCostAndReserveAxis_ContractTerminationMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130630_RestructuringCostAndReserveAxis_OtherRestructuringMember_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130630_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130401to20130630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockCompensationPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockCompensationPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120401to20120630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockCompensationPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20120630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockCompensationPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130401to20130630_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130401to20130630_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120401to20120630_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120401to20120630_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120401to20120630_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130630_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130630_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20120630_StatementBusinessSegmentsAxis_BiodefenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiodefenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20120630_StatementBusinessSegmentsAxis_BiosciencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:BiosciencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20120101to20120630_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130801_BusinessAcquisitionAxis_HealthcareProtectiveProductsDivisionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HealthcareProtectiveProductsDivisionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-08-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20131231_BusinessAcquisitionAxis_ManufacturingEquipmentOfHealthcareProtectiveProductsDivisionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:ManufacturingEquipmentOfHealthcareProtectiveProductsDivisionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130401to20130630_BusinessAcquisitionAxis_HealthcareProtectiveProductsDivisionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HealthcareProtectiveProductsDivisionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20130101to20130630_BusinessAcquisitionAxis_HealthcareProtectiveProductsDivisionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ebs:HealthcareProtectiveProductsDivisionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="U001">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U002">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U003">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U004">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <!--Amendment Flag-->
  <dei:AmendmentFlag contextRef="c20130101to20130630">false</dei:AmendmentFlag>
  <!--Current Fiscal Year End Date-->
  <dei:CurrentFiscalYearEndDate contextRef="c20130101to20130630">--12-31</dei:CurrentFiscalYearEndDate>
  <!--Document Period End Date-->
  <dei:DocumentPeriodEndDate contextRef="c20130101to20130630">2013-06-30</dei:DocumentPeriodEndDate>
  <!--Entity Well-known Seasoned Issuer-->
  <dei:EntityWellKnownSeasonedIssuer contextRef="c20130101to20130630">Yes</dei:EntityWellKnownSeasonedIssuer>
  <!--Entity Voluntary Filers-->
  <dei:EntityVoluntaryFilers contextRef="c20130101to20130630">No</dei:EntityVoluntaryFilers>
  <!--Entity Current Reporting Status-->
  <dei:EntityCurrentReportingStatus contextRef="c20130101to20130630">No</dei:EntityCurrentReportingStatus>
  <!--Entity Filer Category-->
  <dei:EntityFilerCategory contextRef="c20130101to20130630">Accelerated Filer</dei:EntityFilerCategory>
  <!--Entity Registrant Name-->
  <dei:EntityRegistrantName contextRef="c20130101to20130630">Emergent BioSolutions Inc.</dei:EntityRegistrantName>
  <!--Entity Central Index Key-->
  <dei:EntityCentralIndexKey contextRef="c20130101to20130630">0001367644</dei:EntityCentralIndexKey>
  <!--Entity Common Stock, Shares Outstanding-->
  <dei:EntityCommonStockSharesOutstanding contextRef="c20130630" unitRef="U001" decimals="0">36269719</dei:EntityCommonStockSharesOutstanding>
  <!--Document Fiscal Year Focus-->
  <dei:DocumentFiscalYearFocus contextRef="c20130101to20130630">2013</dei:DocumentFiscalYearFocus>
  <!--Document Fiscal Period Focus-->
  <dei:DocumentFiscalPeriodFocus contextRef="c20130101to20130630">Q2</dei:DocumentFiscalPeriodFocus>
  <!--Document Type-->
  <dei:DocumentType contextRef="c20130101to20130630">10-Q</dei:DocumentType>
  <!--Accounts Receivable, Net, Current-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c20130630" unitRef="U002" decimals="-3">54369000</us-gaap:AccountsReceivableNetCurrent>
  <!--Accounts Receivable, Net, Current-->
  <us-gaap:AccountsReceivableNetCurrent contextRef="c20121231" unitRef="U002" decimals="-3">96043000</us-gaap:AccountsReceivableNetCurrent>
  <!--Accounts Payable, Current-->
  <us-gaap:AccountsPayableCurrent contextRef="c20130630" unitRef="U002" decimals="-3">25711000</us-gaap:AccountsPayableCurrent>
  <!--Accounts Payable, Current-->
  <us-gaap:AccountsPayableCurrent contextRef="c20121231" unitRef="U002" decimals="-3">31297000</us-gaap:AccountsPayableCurrent>
  <!--Accrued expenses and other current liabilities-->
  <us-gaap:AccruedLiabilitiesCurrent contextRef="c20130630" unitRef="U002" decimals="-3">1067000</us-gaap:AccruedLiabilitiesCurrent>
  <!--Accrued expenses and other current liabilities-->
  <us-gaap:AccruedLiabilitiesCurrent contextRef="c20121231" unitRef="U002" decimals="-3">1603000</us-gaap:AccruedLiabilitiesCurrent>
  <!--Accumulated other comprehensive loss-->
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c20130630" unitRef="U002" decimals="-3">-3513000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <!--Accumulated other comprehensive loss-->
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c20121231" unitRef="U002" decimals="-3">-4129000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <!--Additional paid-in capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c20130630" unitRef="U002" decimals="-3">236099000</us-gaap:AdditionalPaidInCapital>
  <!--Additional paid-in capital-->
  <us-gaap:AdditionalPaidInCapital contextRef="c20121231" unitRef="U002" decimals="-3">230964000</us-gaap:AdditionalPaidInCapital>
  <!--Antidilutive shares excluded from calculation (in shares)-Stock Compensation Plan [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20130401to20130630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockCompensationPlanMember" unitRef="U001" decimals="-5">3500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive shares excluded from calculation (in shares)-Stock Compensation Plan [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20130101to20130630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockCompensationPlanMember" unitRef="U001" decimals="-5">2700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive shares excluded from calculation (in shares)-Stock Compensation Plan [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20120401to20120630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockCompensationPlanMember" unitRef="U001" decimals="-6">3000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Antidilutive shares excluded from calculation (in shares)-Stock Compensation Plan [Member]-->
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c20120101to20120630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockCompensationPlanMember" unitRef="U001" decimals="-6">3000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20130630" unitRef="U002" decimals="-3">555614000</us-gaap:Assets>
  <!--Assets-->
  <us-gaap:Assets contextRef="c20121231" unitRef="U002" decimals="-3">564230000</us-gaap:Assets>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20130630" unitRef="U002" decimals="-3">248159000</us-gaap:AssetsCurrent>
  <!--Assets, Current-->
  <us-gaap:AssetsCurrent contextRef="c20121231" unitRef="U002" decimals="-3">263347000</us-gaap:AssetsCurrent>
  <!--Assets, Fair Value Disclosure-Fair Value, Inputs, Level 1 [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20130630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="U002" decimals="-3">36323000</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Inputs, Level 2 [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20130630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U002" decimals="-3">0</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Inputs, Level 3 [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20130630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3">0</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20130630" unitRef="U002" decimals="-3">36323000</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Inputs, Level 1 [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20121231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="U002" decimals="-3">42720000</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Inputs, Level 2 [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20121231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U002" decimals="-3">0</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-Fair Value, Inputs, Level 3 [Member]-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20121231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3">0</us-gaap:AssetsFairValueDisclosure>
  <!--Assets, Fair Value Disclosure-->
  <us-gaap:AssetsFairValueDisclosure contextRef="c20121231" unitRef="U002" decimals="-3">42720000</us-gaap:AssetsFairValueDisclosure>
  <!--Asset Purchase Price-Healthcare Protective Products Divisions [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c20130801_BusinessAcquisitionAxis_HealthcareProtectiveProductsDivisionsMember" unitRef="U002" decimals="-5">24200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
  <!--Asset Purchase Price-Manufacturing equipment of Healthcare Protective Products Division [Member]-->
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c20131231_BusinessAcquisitionAxis_ManufacturingEquipmentOfHealthcareProtectiveProductsDivisionMember" unitRef="U002" decimals="-5">1800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20130101to20130630" unitRef="U002" decimals="-3">14577000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Cash and Cash Equivalents, Period Increase (Decrease)-->
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="c20120101to20120630" unitRef="U002" decimals="-3">17942000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20130630" unitRef="U002" decimals="-3">156243000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20121231" unitRef="U002" decimals="-3">141666000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20111231" unitRef="U002" decimals="-3">143901000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and cash equivalents-->
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20120630" unitRef="U002" decimals="-3">161843000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <!--Cash and Cash Equivalents, Fair Value Disclosure-Fair Value, Inputs, Level 1 [Member]-->
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c20130630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="U002" decimals="-3">36323000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <!--Cash and Cash Equivalents, Fair Value Disclosure-Fair Value, Inputs, Level 2 [Member]-->
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c20130630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U002" decimals="-3">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <!--Cash and Cash Equivalents, Fair Value Disclosure-Fair Value, Inputs, Level 3 [Member]-->
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c20130630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <!--Cash and Cash Equivalents, Fair Value Disclosure-->
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c20130630" unitRef="U002" decimals="-3">36323000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <!--Cash and Cash Equivalents, Fair Value Disclosure-Fair Value, Inputs, Level 1 [Member]-->
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c20121231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="U002" decimals="-3">42720000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <!--Cash and Cash Equivalents, Fair Value Disclosure-Fair Value, Inputs, Level 2 [Member]-->
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c20121231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U002" decimals="-3">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <!--Cash and Cash Equivalents, Fair Value Disclosure-Fair Value, Inputs, Level 3 [Member]-->
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c20121231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="-3">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <!--Cash and Cash Equivalents, Fair Value Disclosure-->
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c20121231" unitRef="U002" decimals="-3">42720000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <!--Collaborative Arrangement Disclosure [Text Block]-->
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;font style="font-family: 'Times New Roman', serif; color: #000000; font-size: 9pt; font-weight: bold;"&gt;7.&lt;/font&gt;&lt;font style="font-size: 5.14pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', serif; color: #000000; font-size: 9pt; font-weight: bold;"&gt;Collaboration agreements&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', serif; margin-left: 36pt; font-size: 9pt; font-weight: bold;"&gt;Abbott Laboratories&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;In August 2009, Trubion Pharmaceuticals, Inc. ("Trubion"), which the Company acquired in October 2010, entered into a collaboration agreement with Facet Biotech Corporation, now a wholly-owned subsidiary of Abbott Laboratories ("Abbott"), for the joint worldwide development and commercialization of otlertuzumab (formerly TRU-016). The collaboration agreement was terminated on March 20, 2012 and all rights to otlertuzumab and other CD37-directed protein therapeutics under the collaboration agreement reverted back to the Company.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;During the three and six months ended June 30, 2012, respectively, the Company recorded revenue of $1.4 million and $2.7 million for collaborative research and development services pursuant to the Abbott agreement, which is included in the Company's financial statements of operations as contracts and grants revenue within the Company's Biosciences segment. There was no revenue for the three and six months ended June 30, 2013.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Pfizer Inc.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;In December 2005, Trubion entered into an agreement (the "Pfizer Agreement") with Wyeth Pharmaceuticals, now a wholly-owned subsidiary of Pfizer, for the development and worldwide commercialization of CD20-directed therapeutics. In September 2012, the Pfizer Agreement was terminated. In May 2011, the Company and Pfizer entered into a third amendment to the Pfizer Agreement (the "Biosimilar Amendment") in which the Company released certain restrictions related to the development and commercialization of biosimilar CD20 antibodies. Under the terms of this amendment, the Company is entitled to receive royalty payments in the low-single digits on net sales of certain Pfizer biosimilar products directed to CD20, subject to the satisfaction of specified conditions. The Company's right to receive royalty payments under the Biosimilar Amendment survives termination of the Pfizer Agreement.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;During the three and six months ended June 30, 2012, respectively, the Company recorded revenue of $512,000 and $877,000 for research and development services pursuant to the Pfizer agreement, which is included in the Company's financial statements of operations as contracts and grants revenue within the Company's Biosciences segment. There was no revenue for the three and six months ended June 30, 2013.&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <!--Common stock, par value (in dollars per share)-->
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c20130630" unitRef="U003" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Common stock, par value (in dollars per share)-->
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c20121231" unitRef="U003" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <!--Common stock, $0.001 par value; 100,000,000 shares authorized, 36,589,921 shares issued and 36,186,763 shares outstanding at June 30, 2013; 36,272,550 shares issued and 35,869,392 shares outstanding at December 31, 2012-->
  <us-gaap:CommonStockValue contextRef="c20130630" unitRef="U002" decimals="-3">36000</us-gaap:CommonStockValue>
  <!--Common stock, $0.001 par value; 100,000,000 shares authorized, 36,589,921 shares issued and 36,186,763 shares outstanding at June 30, 2013; 36,272,550 shares issued and 35,869,392 shares outstanding at December 31, 2012-->
  <us-gaap:CommonStockValue contextRef="c20121231" unitRef="U002" decimals="-3">36000</us-gaap:CommonStockValue>
  <!--Common stock, shares issued (in shares)-->
  <us-gaap:CommonStockSharesIssued contextRef="c20130630" unitRef="U001" decimals="0">36589921</us-gaap:CommonStockSharesIssued>
  <!--Common stock, shares issued (in shares)-->
  <us-gaap:CommonStockSharesIssued contextRef="c20121231" unitRef="U001" decimals="0">36272550</us-gaap:CommonStockSharesIssued>
  <!--Common stock, shares authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20130630" unitRef="U001" decimals="0">100000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common stock, shares authorized (in shares)-->
  <us-gaap:CommonStockSharesAuthorized contextRef="c20121231" unitRef="U001" decimals="0">100000000</us-gaap:CommonStockSharesAuthorized>
  <!--Common stock, shares outstanding (in shares)-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20130630" unitRef="U001" decimals="0">36186763</us-gaap:CommonStockSharesOutstanding>
  <!--Common stock, shares outstanding (in shares)-->
  <us-gaap:CommonStockSharesOutstanding contextRef="c20121231" unitRef="U001" decimals="0">35869392</us-gaap:CommonStockSharesOutstanding>
  <!--Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c20130401to20130630" unitRef="U002" decimals="-3">10730000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <!--Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c20120401to20120630" unitRef="U002" decimals="-3">7612000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <!--Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c20130101to20130630" unitRef="U002" decimals="-3">3038000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <!--Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c20120101to20120630" unitRef="U002" decimals="-3">864000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <!--Basis of presentation and consolidation-->
  <us-gaap:ConsolidationPolicyTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Basis of presentation and consolidation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The accompanying unaudited consolidated financial statements include the accounts of Emergent BioSolutions Inc. (the "Company" or "Emergent") and its wholly-owned and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission ("SEC").&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;In the opinion of the Company's management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of June 30, 2013 and the results of operations, comprehensive income and cash flows for the three and six months ended June 30, 2013 and 2012. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <!--Contracts and grants-->
  <us-gaap:ContractsRevenue contextRef="c20130401to20130630" unitRef="U002" decimals="-3">16840000</us-gaap:ContractsRevenue>
  <!--Contracts and grants-->
  <us-gaap:ContractsRevenue contextRef="c20120401to20120630" unitRef="U002" decimals="-3">17218000</us-gaap:ContractsRevenue>
  <!--Contracts and grants-->
  <us-gaap:ContractsRevenue contextRef="c20130101to20130630" unitRef="U002" decimals="-3">29581000</us-gaap:ContractsRevenue>
  <!--Contracts and grants-->
  <us-gaap:ContractsRevenue contextRef="c20120101to20120630" unitRef="U002" decimals="-3">33172000</us-gaap:ContractsRevenue>
  <!--Cost of product sales-->
  <us-gaap:CostOfGoodsSold contextRef="c20130401to20130630" unitRef="U002" decimals="-3">16945000</us-gaap:CostOfGoodsSold>
  <!--Cost of product sales-->
  <us-gaap:CostOfGoodsSold contextRef="c20120401to20120630" unitRef="U002" decimals="-3">13186000</us-gaap:CostOfGoodsSold>
  <!--Cost of product sales-->
  <us-gaap:CostOfGoodsSold contextRef="c20130101to20130630" unitRef="U002" decimals="-3">22643000</us-gaap:CostOfGoodsSold>
  <!--Cost of product sales-->
  <us-gaap:CostOfGoodsSold contextRef="c20120101to20120630" unitRef="U002" decimals="-3">20697000</us-gaap:CostOfGoodsSold>
  <!--Current and deferred income taxes-->
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c20130101to20130630" unitRef="U002" decimals="-3">-135000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <!--Current and deferred income taxes-->
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c20120101to20120630" unitRef="U002" decimals="-3">4080000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <!--Deferred revenue-->
  <us-gaap:DeferredRevenueCurrent contextRef="c20130630" unitRef="U002" decimals="-3">2049000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred revenue-->
  <us-gaap:DeferredRevenueCurrent contextRef="c20121231" unitRef="U002" decimals="-3">1811000</us-gaap:DeferredRevenueCurrent>
  <!--Deferred Tax Assets, Net of Valuation Allowance, Current-->
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="c20130630" unitRef="U002" decimals="-3">1264000</us-gaap:DeferredTaxAssetsNetCurrent>
  <!--Deferred Tax Assets, Net of Valuation Allowance, Current-->
  <us-gaap:DeferredTaxAssetsNetCurrent contextRef="c20121231" unitRef="U002" decimals="-3">1264000</us-gaap:DeferredTaxAssetsNetCurrent>
  <!--Deferred tax assets, net-->
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="c20130630" unitRef="U002" decimals="-3">11087000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <!--Deferred tax assets, net-->
  <us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="c20121231" unitRef="U002" decimals="-3">11087000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <!--Depreciation and amortization-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20130101to20130630" unitRef="U002" decimals="-3">8372000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Depreciation and amortization-->
  <us-gaap:DepreciationDepletionAndAmortization contextRef="c20120101to20120630" unitRef="U002" decimals="-3">4909000</us-gaap:DepreciationDepletionAndAmortization>
  <!--Earnings per share-->
  <us-gaap:EarningsPerShareTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt; vertical-align: top; font-weight: bold; align: right;"&gt;10.&lt;/td&gt;&lt;td style="width: auto; font-family: 'Times New Roman', serif; font-size: 9pt; vertical-align: top; font-weight: bold;"&gt;Earnings per share&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The following table presents the calculation of basic and diluted net income per share:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Three Months Ended June 30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Six Months Ended June 30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;(in thousands, except share and per share data)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;2012&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;2012&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Net income&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;10,484&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;7,632&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,422&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;800&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Weighted-average number of shares&amp;#8212;basic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,144,063&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,182,826&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,056,297&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,114,400&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Dilutive securities&amp;#8212;equity awards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;382,951&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;373,871&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;191,476&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;186,935&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Weighted-average number of shares&amp;#8212;diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,527,014&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,556,697&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,247,773&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,301,335&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Income per share-basic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;0.29&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;0.21&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;0.07&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;0.02&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Income per share-diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;0.29&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;0.21&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;0.07&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;0.02&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 18pt;"&gt;&lt;font style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;font style="font-size: 9pt;"&gt;Stock options with exercise prices in excess of the average per share closing price during the period are not considered in the calculation of fully diluted earnings per share. For the three and six month periods ended June 30, 2013, approximately 3.5 million and 2.7 million stock options, respectively, were excluded from the calculation of diluted earnings per share. For each of the three and six month periods ended June 30, 2012, approximately 3.0 million stock options were excluded from the calculation of diluted earnings per &lt;font style="font-size: 9pt;"&gt;share&lt;/font&gt;&lt;/font&gt;&lt;font style="font-size: 9pt;"&gt;.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <!--Income per share - basic-->
  <us-gaap:EarningsPerShareBasic contextRef="c20130401to20130630" unitRef="U003" decimals="2">0.29</us-gaap:EarningsPerShareBasic>
  <!--Income per share - basic-->
  <us-gaap:EarningsPerShareBasic contextRef="c20120401to20120630" unitRef="U003" decimals="2">0.21</us-gaap:EarningsPerShareBasic>
  <!--Income per share - basic-->
  <us-gaap:EarningsPerShareBasic contextRef="c20130101to20130630" unitRef="U003" decimals="2">0.07</us-gaap:EarningsPerShareBasic>
  <!--Income per share - basic-->
  <us-gaap:EarningsPerShareBasic contextRef="c20120101to20120630" unitRef="U003" decimals="2">0.02</us-gaap:EarningsPerShareBasic>
  <!--Income per share - diluted-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20130401to20130630" unitRef="U003" decimals="2">0.29</us-gaap:EarningsPerShareDiluted>
  <!--Income per share - diluted-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20120401to20120630" unitRef="U003" decimals="2">0.21</us-gaap:EarningsPerShareDiluted>
  <!--Income per share - diluted-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20130101to20130630" unitRef="U003" decimals="2">0.07</us-gaap:EarningsPerShareDiluted>
  <!--Income per share - diluted-->
  <us-gaap:EarningsPerShareDiluted contextRef="c20120101to20120630" unitRef="U003" decimals="2">0.02</us-gaap:EarningsPerShareDiluted>
  <!--Effect of exchange rate changes on cash and cash equivalents-->
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c20130101to20130630" unitRef="U002" decimals="-3">43000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <!--Effect of exchange rate changes on cash and cash equivalents-->
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c20120101to20120630" unitRef="U002" decimals="-3">31000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <!--Employee-related Liabilities, Current-->
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c20130630" unitRef="U002" decimals="-3">15481000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <!--Employee-related Liabilities, Current-->
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c20121231" unitRef="U002" decimals="-3">22726000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <!--Excess Tax Benefit from Share-based Compensation, Operating Activities-->
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="c20130101to20130630" unitRef="U002" decimals="-3">1757000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <!--Excess Tax Benefit from Share-based Compensation, Operating Activities-->
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="c20120101to20120630" unitRef="U002" decimals="-3">1307000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <!--Excess tax benefits from stock-based compensation-->
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="c20130101to20130630" unitRef="U002" decimals="-3">1757000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <!--Excess tax benefits from stock-based compensation-->
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="c20120101to20120630" unitRef="U002" decimals="-3">1307000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <!--Fair Value Disclosures [Text Block]-->
  <us-gaap:FairValueDisclosuresTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;font style="font-family: 'Times New Roman', serif; color: #000000; font-size: 9pt; font-weight: bold;"&gt;2.&lt;/font&gt;&lt;font style="font-size: 5.14pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', serif; color: #000000; font-size: 9pt; font-weight: bold;"&gt;Fair value measurements&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: top;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;At June 30, 2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Level 1&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Level 2&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Level 3&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Investment in money market funds (1)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,323&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,323&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,323&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,323&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: top;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;At December 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Level 1&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Level 2&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Level 3&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Investment in money market funds (1)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;42,720&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;42,720&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;42,720&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;42,720&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 54pt; vertical-align: top; align: right;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; color: #000000; margin-left: 36pt; font-size: 9pt;"&gt;(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', serif; color: #000000; font-size: 9pt;"&gt;Included in cash and cash equivalents in accompanying consolidated balance sheets.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;As of June 30, 2013 and 2012, the Company did not have any transfers between Level 1 and Level 2 assets or liabilities.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The fair value of the contingent value right ("CVR") obligations is based on management's assessment of certain development and collaboration milestones, which are inputs that have no observable market (Level 3). The obligation is measured using a discounted cash flow model. As of June 30, 2012, the Company recorded a decrease in the CVR obligations of $3.0 million due to Pfizer ceasing development of programs related to the CVR milestones and made a $1.7 million CVR payment under the Company's agreement with Abbott. The adjustment to fair value is classified in the Company's statement of operations as research and development expense within the Company's Biosciences segment. &amp;#160;As of June 30, 2013 and 2012, the Company had no assets or liabilities measured at fair value using significant unobservable inputs (Level 3).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis, as documented above, from those measured at fair value on a nonrecurring basis. For the six months ended June 30, 2013, no assets or liabilities were measured at fair value on a nonrecurring basis. For the year ended December 31, 2012, the Company's SBI-087 in-process research and development ("IPR&amp;amp;D") asset, which was categorized as a level 3 fair value measurement, was the only asset or liability measured at fair value on a nonrecurring basis (see Note 4).&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <!--Goodwill-->
  <us-gaap:Goodwill contextRef="c20130630" unitRef="U002" decimals="-3">5502000</us-gaap:Goodwill>
  <!--Goodwill-->
  <us-gaap:Goodwill contextRef="c20121231" unitRef="U002" decimals="-3">5502000</us-gaap:Goodwill>
  <!--In-process research and development and goodwill-->
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;font style="font-family: 'Times New Roman', serif; color: #000000; font-size: 9pt; font-weight: bold;"&gt;4.&lt;/font&gt;&lt;font style="font-size: 5.14pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', serif; color: #000000; font-size: 9pt; font-weight: bold;"&gt;In-process research and development and goodwill&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;&lt;font style="background-color: #ffffff; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;During the six months ended June 30, 2012, Pfizer terminated its development programs with respect to the Company's SBI-087 product candidate. The Company considered this termination a potential indicator of impairment of the related SBI-087 IPR&amp;amp;D asset, and assessed the fair value of this asset. As part of the assessment, the Company considered the impact of Pfizer's decision, along with the Company's decision to no longer pursue further development of this asset due to reduced overall probability of success and increased development costs for the product candidate. As a result, the Company recorded an impairment charge of $9.6 million during the six months ended June 30, 2012, which represented the entire carrying value of the SBI-087 IPR&amp;amp;D asset. &lt;/font&gt;This charge is classified in the Company's statement of operations as impairment of in-process research and development, within the Company's Biosciences segment.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;As a result of the impairment of the SBI-087 IPR&amp;amp;D asset, the Company also performed an analysis of the Biosciences therapeutic reporting unit, which contains all goodwill reported on the Company's consolidated balance sheets for the period ended June 30, 2012. Based on the analysis, the Company concluded that goodwill was not more likely than not impaired and therefore an interim impairment analysis was deemed unnecessary.&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <!--Impairment of in-process research and development-->
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c20130401to20130630" unitRef="U002" decimals="-3">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <!--Impairment of in-process research and development-->
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c20120401to20120630" unitRef="U002" decimals="-3">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <!--Impairment of in-process research and development-->
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c20130101to20130630" unitRef="U002" decimals="-3">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <!--Impairment of in-process research and development-->
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c20120101to20120630" unitRef="U002" decimals="-3">9600000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <!--Impairment of IPR&D assets-->
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c20130101to20130630" unitRef="U002" decimals="-5">9600000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <!--Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c20130401to20130630" unitRef="U002" decimals="-3">14737000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c20120401to20120630" unitRef="U002" decimals="-3">9589000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c20130101to20130630" unitRef="U002" decimals="-3">1416000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest-->
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c20120101to20120630" unitRef="U002" decimals="-3">-2076000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <!--Provision for (benefit from) income taxes-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20130401to20130630" unitRef="U002" decimals="-3">4381000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Provision for (benefit from) income taxes-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20120401to20120630" unitRef="U002" decimals="-3">4043000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Provision for (benefit from) income taxes-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20130101to20130630" unitRef="U002" decimals="-3">-135000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Provision for (benefit from) income taxes-->
  <us-gaap:IncomeTaxExpenseBenefit contextRef="c20120101to20120630" unitRef="U002" decimals="-3">403000</us-gaap:IncomeTaxExpenseBenefit>
  <!--Income tax receivable, net-->
  <us-gaap:IncomeTaxesReceivable contextRef="c20130630" unitRef="U002" decimals="-3">6502000</us-gaap:IncomeTaxesReceivable>
  <!--Income tax receivable, net-->
  <us-gaap:IncomeTaxesReceivable contextRef="c20121231" unitRef="U002" decimals="-3">0</us-gaap:IncomeTaxesReceivable>
  <!--Increase (Decrease) in Accounts Receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c20130101to20130630" unitRef="U002" decimals="-3">-41674000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Increase (Decrease) in Accounts Receivable-->
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c20120101to20120630" unitRef="U002" decimals="-3">-27338000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <!--Accounts payable-->
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c20130101to20130630" unitRef="U002" decimals="-3">-6199000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <!--Accounts payable-->
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c20120101to20120630" unitRef="U002" decimals="-3">-7068000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <!--Accrued expenses and other liabilities-->
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c20130101to20130630" unitRef="U002" decimals="-3">-619000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <!--Accrued expenses and other liabilities-->
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c20120101to20120630" unitRef="U002" decimals="-3">488000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <!--Increase (Decrease) in Deferred Revenue-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c20130101to20130630" unitRef="U002" decimals="-3">238000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--Increase (Decrease) in Deferred Revenue-->
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c20120101to20120630" unitRef="U002" decimals="-3">142000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <!--Increase (Decrease) in Inventories-->
  <us-gaap:IncreaseDecreaseInInventories contextRef="c20130101to20130630" unitRef="U002" decimals="-3">3421000</us-gaap:IncreaseDecreaseInInventories>
  <!--Increase (Decrease) in Inventories-->
  <us-gaap:IncreaseDecreaseInInventories contextRef="c20120101to20120630" unitRef="U002" decimals="-3">1347000</us-gaap:IncreaseDecreaseInInventories>
  <!--Accrued compensation-->
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c20130101to20130630" unitRef="U002" decimals="-3">-7130000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <!--Accrued compensation-->
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c20120101to20120630" unitRef="U002" decimals="-3">-6900000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <!--Increase (Decrease) in Income Taxes Receivable-->
  <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c20130101to20130630" unitRef="U002" decimals="-3">7999000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
  <!--Increase (Decrease) in Income Taxes Receivable-->
  <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c20120101to20120630" unitRef="U002" decimals="-3">2163000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20130101to20130630" unitRef="U002" decimals="-3">1734000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Increase (Decrease) in Prepaid Expense and Other Assets-->
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c20120101to20120630" unitRef="U002" decimals="-3">-888000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <!--Dilutive securities-equity awards (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c20130401to20130630" unitRef="U001" decimals="0">382951</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <!--Dilutive securities-equity awards (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c20120401to20120630" unitRef="U001" decimals="0">373871</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <!--Dilutive securities-equity awards (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c20130101to20130630" unitRef="U001" decimals="0">191476</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <!--Dilutive securities-equity awards (in shares)-->
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c20120101to20120630" unitRef="U001" decimals="0">186935</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20130401to20130630" unitRef="U002" decimals="-3">3000</us-gaap:InterestExpense>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20120401to20120630" unitRef="U002" decimals="-3">0</us-gaap:InterestExpense>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20130101to20130630" unitRef="U002" decimals="-3">14000</us-gaap:InterestExpense>
  <!--Interest Expense-->
  <us-gaap:InterestExpense contextRef="c20120101to20120630" unitRef="U002" decimals="-3">6000</us-gaap:InterestExpense>
  <!--Inventory, Net-->
  <us-gaap:InventoryNet contextRef="c20130630" unitRef="U002" decimals="-3">18582000</us-gaap:InventoryNet>
  <!--Inventory, Net-->
  <us-gaap:InventoryNet contextRef="c20121231" unitRef="U002" decimals="-3">15161000</us-gaap:InventoryNet>
  <!--Finished goods-->
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c20130630" unitRef="U002" decimals="-3">5009000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <!--Finished goods-->
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c20121231" unitRef="U002" decimals="-3">2615000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <!--Inventory Disclosure [Text Block]-->
  <us-gaap:InventoryDisclosureTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;font style="font-family: 'Times New Roman', serif; color: #000000; font-size: 9pt; font-weight: bold;"&gt;3.&lt;/font&gt;&lt;font style="font-size: 5.14pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', serif; color: #000000; font-size: 9pt; font-weight: bold;"&gt;Inventories&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Inventories consist of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;June 30,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;2012&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Raw materials and supplies&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,613&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,733&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Work-in-process&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;10,960&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;9,813&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Finished goods&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;5,009&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,615&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 76%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Total inventories&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;18,582&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;15,161&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <!--Raw materials and supplies-->
  <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="c20130630" unitRef="U002" decimals="-3">2613000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
  <!--Raw materials and supplies-->
  <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="c20121231" unitRef="U002" decimals="-3">2733000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
  <!--Work-in-process-->
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c20130630" unitRef="U002" decimals="-3">10960000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <!--Work-in-process-->
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c20121231" unitRef="U002" decimals="-3">9813000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <!--Interest income-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20130401to20130630" unitRef="U002" decimals="-3">10000</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20120401to20120630" unitRef="U002" decimals="-3">29000</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20130101to20130630" unitRef="U002" decimals="-3">33000</us-gaap:InvestmentIncomeInterest>
  <!--Interest income-->
  <us-gaap:InvestmentIncomeInterest contextRef="c20120101to20120630" unitRef="U002" decimals="-3">54000</us-gaap:InvestmentIncomeInterest>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20130630" unitRef="U002" decimals="-3">48778000</us-gaap:LiabilitiesCurrent>
  <!--Liabilities, Current-->
  <us-gaap:LiabilitiesCurrent contextRef="c20121231" unitRef="U002" decimals="-3">61907000</us-gaap:LiabilitiesCurrent>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20130630" unitRef="U002" decimals="-3">555614000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Liabilities and Equity-->
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c20121231" unitRef="U002" decimals="-3">564230000</us-gaap:LiabilitiesAndStockholdersEquity>
  <!--Liabilities-->
  <us-gaap:Liabilities contextRef="c20130630" unitRef="U002" decimals="-3">106532000</us-gaap:Liabilities>
  <!--Liabilities-->
  <us-gaap:Liabilities contextRef="c20121231" unitRef="U002" decimals="-3">122102000</us-gaap:Liabilities>
  <!--Long-term indebtedness, current portion-->
  <us-gaap:LongTermDebtCurrent contextRef="c20130630" unitRef="U002" decimals="-3">4470000</us-gaap:LongTermDebtCurrent>
  <!--Long-term indebtedness, current portion-->
  <us-gaap:LongTermDebtCurrent contextRef="c20121231" unitRef="U002" decimals="-3">4470000</us-gaap:LongTermDebtCurrent>
  <!--Long-term Debt, Excluding Current Maturities-->
  <us-gaap:LongTermDebtNoncurrent contextRef="c20130630" unitRef="U002" decimals="-3">56069000</us-gaap:LongTermDebtNoncurrent>
  <!--Long-term Debt, Excluding Current Maturities-->
  <us-gaap:LongTermDebtNoncurrent contextRef="c20121231" unitRef="U002" decimals="-3">58304000</us-gaap:LongTermDebtNoncurrent>
  <!--Noncontrolling Interest Disclosure [Text Block]-->
  <us-gaap:MinorityInterestDisclosureTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;font style="font-family: 'Times New Roman', serif; color: #000000; font-size: 9pt; font-weight: bold;"&gt;6.&lt;/font&gt;&lt;font style="font-size: 5.14pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', serif; color: #000000; font-size: 9pt; font-weight: bold;"&gt;Variable interest entities&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;In July 2008, the Company entered into a collaboration with the University of Oxford ("Oxford") and certain Oxford researchers to advance a vaccine product candidate for tuberculosis, resulting in the formation of the Oxford-Emergent Tuberculosis Consortium ("OETC"). The Company has a 51% equity interest in OETC. In February 2013, the Company published clinical trial data which showed its tuberculosis vaccine product candidate did not confer statistically significant protection for the tuberculosis disease or infection in infants from those vaccinated at birth with the Baccile Calmette-Guerin vaccine. As a result of this clinical trial data, the Company is ceasing development work on this product candidate and expects future funding of OETC to be minimal while the OETC entity is liquidated.&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The Company evaluates its variable interests in OETC on a quarterly basis and has determined that it is the primary beneficiary as it has directed the activities of OETC that most significantly impact OETC's economic performance and will absorb the majority of expected losses. Accordingly, the Company consolidates OETC. As of June 30, 2013 and 2012, respectively, assets of $291,000 and $3.5 million and liabilities of $229,000 and $1.3 million related to OETC were included within the Company's consolidated balance sheets. During the three and six months ended June 30, 2013, respectively, OETC incurred net losses of $262,000 and $1.8 million, of which $133,000 and $905,000 are included in the Company's consolidated statement of operations. During the three and six months ended June 30, 2012, respectively, OETC incurred net losses of $4.2 million and $6.5 million, of which $2.1 million and $3.3 million are included in the Company's consolidated statement of operations.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;In conjunction with the establishment of OETC, the Company granted a put option to Oxford and certain Oxford researchers whereby the Company may be required to acquire all of the OETC shares held by Oxford and the Oxford researchers at the fair market value of the underlying shares. This put option is contingent upon the satisfaction of a number of conditions that must exist or occur subsequent to the granting by the European Commission of marketing authorization for the OETC-sponsored tuberculosis vaccine product candidate. The Company accounts for the put option in accordance with the accounting provisions related to derivatives and distinguishing liabilities from equity. In accordance with these provisions, the Company has determined that the put option had no value as of June 30, 2013.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The following is a summary of the stockholders' equity attributable to the Company and the noncontrolling interests:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Emergent&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Noncontrolling&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;BioSolutions Inc.&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Interests&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Stockholders' equity at December 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;441,358&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;770&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;442,128&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Non-cash development expenses from variable interest entities&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(347&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(347&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,422&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(871&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;1,551&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;5,750&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;5,750&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Stockholders' equity at June 30, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;449,530&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(448&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;449,082&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
  <!--Noncontrolling interest in subsidiaries-->
  <us-gaap:MinorityInterest contextRef="c20130630" unitRef="U002" decimals="-3">-448000</us-gaap:MinorityInterest>
  <!--Noncontrolling interest in subsidiaries-->
  <us-gaap:MinorityInterest contextRef="c20121231" unitRef="U002" decimals="-3">770000</us-gaap:MinorityInterest>
  <!--Net Cash Provided by (Used in) Investing Activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c20130101to20130630" unitRef="U002" decimals="-3">-14123000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net Cash Provided by (Used in) Investing Activities-->
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c20120101to20120630" unitRef="U002" decimals="-3">-17190000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <!--Net Cash Provided by (Used in) Financing Activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c20130101to20130630" unitRef="U002" decimals="-3">455000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net Cash Provided by (Used in) Financing Activities-->
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c20120101to20120630" unitRef="U002" decimals="-3">2923000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <!--Net Cash Provided by (Used in) Operating Activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c20130101to20130630" unitRef="U002" decimals="-3">28202000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net Cash Provided by (Used in) Operating Activities-->
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c20120101to20120630" unitRef="U002" decimals="-3">32178000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <!--Net Income (Loss) Attributable to Parent-->
  <us-gaap:NetIncomeLoss contextRef="c20130401to20130630" unitRef="U002" decimals="-3">10484000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-->
  <us-gaap:NetIncomeLoss contextRef="c20120401to20120630" unitRef="U002" decimals="-3">7632000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-->
  <us-gaap:NetIncomeLoss contextRef="c20130101to20130630" unitRef="U002" decimals="-3">2422000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-->
  <us-gaap:NetIncomeLoss contextRef="c20120101to20120630" unitRef="U002" decimals="-3">800000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-Biodefense [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20130401to20130630_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U002" decimals="-3">24996000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-Biosciences [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20130401to20130630_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">-14156000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-All Other [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20130401to20130630_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U002" decimals="-3">-356000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-Biodefense [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20120401to20120630_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U002" decimals="-3">24335000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-Biosciences [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20120401to20120630_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">-14963000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-All Other [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20120401to20120630_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U002" decimals="-3">-1740000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-Biodefense [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20130101to20130630_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U002" decimals="-3">29606000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-Biosciences [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20130101to20130630_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">-25528000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-All Other [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20130101to20130630_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U002" decimals="-3">-1656000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-Biodefense [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20120101to20120630_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U002" decimals="-3">38601000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-Biosciences [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20120101to20120630_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">-34854000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Parent-All Other [Member]-->
  <us-gaap:NetIncomeLoss contextRef="c20120101to20120630_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U002" decimals="-3">-2947000</us-gaap:NetIncomeLoss>
  <!--Net Income (Loss) Attributable to Noncontrolling Interest-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20130401to20130630" unitRef="U002" decimals="-3">-128000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--Net Income (Loss) Attributable to Noncontrolling Interest-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20120401to20120630" unitRef="U002" decimals="-3">-2086000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--Net Income (Loss) Attributable to Noncontrolling Interest-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20130101to20130630" unitRef="U002" decimals="-3">-871000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--Net Income (Loss) Attributable to Noncontrolling Interest-->
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c20120101to20120630" unitRef="U002" decimals="-3">-3279000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20130401to20130630" unitRef="U002" decimals="-3">25000</us-gaap:NonoperatingIncomeExpense>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20120401to20120630" unitRef="U002" decimals="-3">936000</us-gaap:NonoperatingIncomeExpense>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20130101to20130630" unitRef="U002" decimals="-3">54000</us-gaap:NonoperatingIncomeExpense>
  <!--Nonoperating Income (Expense)-->
  <us-gaap:NonoperatingIncomeExpense contextRef="c20120101to20120630" unitRef="U002" decimals="-3">1809000</us-gaap:NonoperatingIncomeExpense>
  <!--Number of business segments-->
  <us-gaap:NumberOfReportableSegments contextRef="c20130101to20130630" unitRef="U004" decimals="INF">2</us-gaap:NumberOfReportableSegments>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20130401to20130630" unitRef="U002" decimals="-3">14712000</us-gaap:OperatingIncomeLoss>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20120401to20120630" unitRef="U002" decimals="-3">8653000</us-gaap:OperatingIncomeLoss>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20130101to20130630" unitRef="U002" decimals="-3">1362000</us-gaap:OperatingIncomeLoss>
  <!--Operating Income (Loss)-->
  <us-gaap:OperatingIncomeLoss contextRef="c20120101to20120630" unitRef="U002" decimals="-3">-3885000</us-gaap:OperatingIncomeLoss>
  <!--Foreign currency translations, net of tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20130401to20130630" unitRef="U002" decimals="-3">246000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20120401to20120630" unitRef="U002" decimals="-3">-20000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20130101to20130630" unitRef="U002" decimals="-3">616000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Foreign currency translations, net of tax-->
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c20120101to20120630" unitRef="U002" decimals="-3">64000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <!--Other assets-->
  <us-gaap:OtherAssetsNoncurrent contextRef="c20130630" unitRef="U002" decimals="-3">562000</us-gaap:OtherAssetsNoncurrent>
  <!--Other assets-->
  <us-gaap:OtherAssetsNoncurrent contextRef="c20121231" unitRef="U002" decimals="-3">730000</us-gaap:OtherAssetsNoncurrent>
  <!--Other Noncash Income (Expense)-->
  <us-gaap:OtherNoncashIncomeExpense contextRef="c20130101to20130630" unitRef="U002" decimals="-3">10000</us-gaap:OtherNoncashIncomeExpense>
  <!--Other Noncash Income (Expense)-->
  <us-gaap:OtherNoncashIncomeExpense contextRef="c20120101to20120630" unitRef="U002" decimals="-3">55000</us-gaap:OtherNoncashIncomeExpense>
  <!--Non-cash development expenses from joint venture-->
  <us-gaap:OtherNoncashExpense contextRef="c20130101to20130630" unitRef="U002" decimals="-3">-347000</us-gaap:OtherNoncashExpense>
  <!--Non-cash development expenses from joint venture-->
  <us-gaap:OtherNoncashExpense contextRef="c20120101to20120630" unitRef="U002" decimals="-3">3632000</us-gaap:OtherNoncashExpense>
  <!--Other income (expense), net-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20130401to20130630" unitRef="U002" decimals="-3">18000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other income (expense), net-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20120401to20120630" unitRef="U002" decimals="-3">907000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other income (expense), net-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20130101to20130630" unitRef="U002" decimals="-3">35000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other income (expense), net-->
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="c20120101to20120630" unitRef="U002" decimals="-3">1761000</us-gaap:OtherNonoperatingIncomeExpense>
  <!--Other liabilities-->
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="c20130630" unitRef="U002" decimals="-3">1685000</us-gaap:OtherLiabilitiesNoncurrent>
  <!--Other liabilities-->
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="c20121231" unitRef="U002" decimals="-3">1891000</us-gaap:OtherLiabilitiesNoncurrent>
  <!--Payments for Restructuring-Biosciences [Member]-Termination benefits [Member]-->
  <us-gaap:PaymentsForRestructuring contextRef="c20130101to20130630_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">1660000</us-gaap:PaymentsForRestructuring>
  <!--Payments for Restructuring-Contract termination costs [Member]-Biosciences [Member]-->
  <us-gaap:PaymentsForRestructuring contextRef="c20130101to20130630_RestructuringCostAndReserveAxis_ContractTerminationMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">431000</us-gaap:PaymentsForRestructuring>
  <!--Payments for Restructuring-Biosciences [Member]-Other costs [Member]-->
  <us-gaap:PaymentsForRestructuring contextRef="c20130101to20130630_RestructuringCostAndReserveAxis_OtherRestructuringMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">134000</us-gaap:PaymentsForRestructuring>
  <!--Payments for Restructuring-Biosciences [Member]-->
  <us-gaap:PaymentsForRestructuring contextRef="c20130101to20130630_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">2225000</us-gaap:PaymentsForRestructuring>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20130101to20130630" unitRef="U002" decimals="-3">14123000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Payments to Acquire Property, Plant, and Equipment-->
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c20120101to20120630" unitRef="U002" decimals="-3">30921000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <!--Preferred stock, par value (in dollars per share)-->
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c20130630" unitRef="U003" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <!--Preferred stock, par value (in dollars per share)-->
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c20121231" unitRef="U003" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <!--Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively-->
  <us-gaap:PreferredStockValue contextRef="c20130630" unitRef="U002" decimals="-3">0</us-gaap:PreferredStockValue>
  <!--Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively-->
  <us-gaap:PreferredStockValue contextRef="c20121231" unitRef="U002" decimals="-3">0</us-gaap:PreferredStockValue>
  <!--Preferred stock, shares issued (in shares)-->
  <us-gaap:PreferredStockSharesIssued contextRef="c20130630" unitRef="U001" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <!--Preferred stock, shares issued (in shares)-->
  <us-gaap:PreferredStockSharesIssued contextRef="c20121231" unitRef="U001" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <!--Preferred stock, shares authorized (in shares)-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c20130630" unitRef="U001" decimals="0">15000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Preferred stock, shares authorized (in shares)-->
  <us-gaap:PreferredStockSharesAuthorized contextRef="c20121231" unitRef="U001" decimals="0">15000000</us-gaap:PreferredStockSharesAuthorized>
  <!--Preferred stock, shares outstanding (in shares)-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c20130630" unitRef="U001" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <!--Preferred stock, shares outstanding (in shares)-->
  <us-gaap:PreferredStockSharesOutstanding contextRef="c20121231" unitRef="U001" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <!--Prepaid expenses and other current assets-->
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c20130630" unitRef="U002" decimals="-3">11199000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <!--Prepaid expenses and other current assets-->
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c20121231" unitRef="U002" decimals="-3">9213000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <!--Proceeds from sale of assets-->
  <us-gaap:ProceedsFromSalesOfAssetsInvestingActivities contextRef="c20130101to20130630" unitRef="U002" decimals="-3">0</us-gaap:ProceedsFromSalesOfAssetsInvestingActivities>
  <!--Proceeds from sale of assets-->
  <us-gaap:ProceedsFromSalesOfAssetsInvestingActivities contextRef="c20120101to20120630" unitRef="U002" decimals="-3">11765000</us-gaap:ProceedsFromSalesOfAssetsInvestingActivities>
  <!--Proceeds from (Repayments of) Restricted Cash, Financing Activities-->
  <us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities contextRef="c20130101to20130630" unitRef="U002" decimals="-3">0</us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities>
  <!--Proceeds from (Repayments of) Restricted Cash, Financing Activities-->
  <us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities contextRef="c20120101to20120630" unitRef="U002" decimals="-3">220000</us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities>
  <!--Issuance of common stock subject to employee equity plans-->
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="c20130101to20130630" unitRef="U002" decimals="-3">933000</us-gaap:ProceedsFromStockOptionsExercised>
  <!--Issuance of common stock subject to employee equity plans-->
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="c20120101to20120630" unitRef="U002" decimals="-3">401000</us-gaap:ProceedsFromStockOptionsExercised>
  <!--Proceeds from maturity of investments-->
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c20130101to20130630" unitRef="U002" decimals="-3">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <!--Proceeds from maturity of investments-->
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c20120101to20120630" unitRef="U002" decimals="-3">1966000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <!--Net income (loss)-->
  <us-gaap:ProfitLoss contextRef="c20130401to20130630" unitRef="U002" decimals="-3">10356000</us-gaap:ProfitLoss>
  <!--Net income (loss)-->
  <us-gaap:ProfitLoss contextRef="c20120401to20120630" unitRef="U002" decimals="-3">5546000</us-gaap:ProfitLoss>
  <!--Net income (loss)-->
  <us-gaap:ProfitLoss contextRef="c20130101to20130630" unitRef="U002" decimals="-3">1551000</us-gaap:ProfitLoss>
  <!--Net income (loss)-->
  <us-gaap:ProfitLoss contextRef="c20120101to20120630" unitRef="U002" decimals="-3">-2479000</us-gaap:ProfitLoss>
  <!--Net income (loss)-Oxford Emergent Tuberculosis Consortium [Member]-->
  <us-gaap:ProfitLoss contextRef="c20130401to20130630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember" unitRef="U002" decimals="0">-262000</us-gaap:ProfitLoss>
  <!--Net income (loss)-Oxford Emergent Tuberculosis Consortium [Member]-->
  <us-gaap:ProfitLoss contextRef="c20130101to20130630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember" unitRef="U002" decimals="-5">-1800000</us-gaap:ProfitLoss>
  <!--Net income (loss)-Oxford Emergent Tuberculosis Consortium [Member]-->
  <us-gaap:ProfitLoss contextRef="c20120401to20120630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember" unitRef="U002" decimals="-5">-4200000</us-gaap:ProfitLoss>
  <!--Net income (loss)-Oxford Emergent Tuberculosis Consortium [Member]-->
  <us-gaap:ProfitLoss contextRef="c20120101to20120630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember" unitRef="U002" decimals="-5">-6500000</us-gaap:ProfitLoss>
  <!--Net income (loss)-Emergent BioSolutions Inc. [Member]-->
  <us-gaap:ProfitLoss contextRef="c20130101to20130630_StatementEquityComponentsAxis_ParentMember" unitRef="U002" decimals="-3">2422000</us-gaap:ProfitLoss>
  <!--Net income (loss)-Noncontrolling Interests [Member]-->
  <us-gaap:ProfitLoss contextRef="c20130101to20130630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3">-871000</us-gaap:ProfitLoss>
  <!--Property, plant and equipment, net-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20130630" unitRef="U002" decimals="-3">248504000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Property, plant and equipment, net-->
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="c20121231" unitRef="U002" decimals="-3">241764000</us-gaap:PropertyPlantAndEquipmentNet>
  <!--Quantifying Misstatement in Current Year Financial Statements, Amount-->
  <us-gaap:QuantifyingMisstatementInCurrentYearFinancialStatementsAmount contextRef="c20130101to20130630" unitRef="U002" decimals="-5">2600000</us-gaap:QuantifyingMisstatementInCurrentYearFinancialStatementsAmount>
  <!--Repayments of Long-term Debt-->
  <us-gaap:RepaymentsOfLongTermDebt contextRef="c20130101to20130630" unitRef="U002" decimals="-3">2235000</us-gaap:RepaymentsOfLongTermDebt>
  <!--Repayments of Long-term Debt-->
  <us-gaap:RepaymentsOfLongTermDebt contextRef="c20120101to20120630" unitRef="U002" decimals="-3">8670000</us-gaap:RepaymentsOfLongTermDebt>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20130401to20130630" unitRef="U002" decimals="-3">30278000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20120401to20120630" unitRef="U002" decimals="-3">30645000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20130101to20130630" unitRef="U002" decimals="-3">61002000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Research and development-->
  <us-gaap:ResearchAndDevelopmentExpense contextRef="c20120101to20120630" unitRef="U002" decimals="-3">56891000</us-gaap:ResearchAndDevelopmentExpense>
  <!--Inception to date costs incurred-Biosciences [Member]-Termination benefits [Member]-->
  <us-gaap:RestructuringAndRelatedCostCostIncurredToDate contextRef="c20130101to20130630_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">2114000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate>
  <!--Inception to date costs incurred-Contract termination costs [Member]-Biosciences [Member]-->
  <us-gaap:RestructuringAndRelatedCostCostIncurredToDate contextRef="c20130101to20130630_RestructuringCostAndReserveAxis_ContractTerminationMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">431000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate>
  <!--Inception to date costs incurred-Biosciences [Member]-Other costs [Member]-->
  <us-gaap:RestructuringAndRelatedCostCostIncurredToDate contextRef="c20130101to20130630_RestructuringCostAndReserveAxis_OtherRestructuringMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">261000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate>
  <!--Inception to date costs incurred-Biosciences [Member]-->
  <us-gaap:RestructuringAndRelatedCostCostIncurredToDate contextRef="c20130101to20130630_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">2806000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate>
  <!--Inception to date costs incurred-Biosciences [Member]-Termination benefits [Member]-->
  <us-gaap:RestructuringAndRelatedCostCostIncurredToDate contextRef="c20130101to20131231_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">2114000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate>
  <!--Inception to date costs incurred-Contract termination costs [Member]-Biosciences [Member]-->
  <us-gaap:RestructuringAndRelatedCostCostIncurredToDate contextRef="c20130101to20131231_RestructuringCostAndReserveAxis_ContractTerminationMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">431000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate>
  <!--Inception to date costs incurred-Biosciences [Member]-Other costs [Member]-->
  <us-gaap:RestructuringAndRelatedCostCostIncurredToDate contextRef="c20130101to20131231_RestructuringCostAndReserveAxis_OtherRestructuringMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">261000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate>
  <!--Inception to date costs incurred-Biosciences [Member]-->
  <us-gaap:RestructuringAndRelatedCostCostIncurredToDate contextRef="c20130101to20131231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">2806000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate>
  <!--Restructuring expenses-Biosciences [Member]-Termination benefits [Member]-->
  <us-gaap:RestructuringCharges contextRef="c20130101to20130630_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">2114000</us-gaap:RestructuringCharges>
  <!--Restructuring expenses-Contract termination costs [Member]-Biosciences [Member]-->
  <us-gaap:RestructuringCharges contextRef="c20130101to20130630_RestructuringCostAndReserveAxis_ContractTerminationMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">431000</us-gaap:RestructuringCharges>
  <!--Restructuring expenses-Biosciences [Member]-Other costs [Member]-->
  <us-gaap:RestructuringCharges contextRef="c20130101to20130630_RestructuringCostAndReserveAxis_OtherRestructuringMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">134000</us-gaap:RestructuringCharges>
  <!--Restructuring expenses-Biosciences [Member]-->
  <us-gaap:RestructuringCharges contextRef="c20130101to20130630_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">2679000</us-gaap:RestructuringCharges>
  <!--Restructuring Reserve-Biosciences [Member]-Termination benefits [Member]-->
  <us-gaap:RestructuringReserve contextRef="c20121231_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">0</us-gaap:RestructuringReserve>
  <!--Restructuring Reserve-Contract termination costs [Member]-Biosciences [Member]-->
  <us-gaap:RestructuringReserve contextRef="c20121231_RestructuringCostAndReserveAxis_ContractTerminationMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">0</us-gaap:RestructuringReserve>
  <!--Restructuring Reserve-Biosciences [Member]-Other costs [Member]-->
  <us-gaap:RestructuringReserve contextRef="c20121231_RestructuringCostAndReserveAxis_OtherRestructuringMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">0</us-gaap:RestructuringReserve>
  <!--Restructuring Reserve-Biosciences [Member]-->
  <us-gaap:RestructuringReserve contextRef="c20121231_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">0</us-gaap:RestructuringReserve>
  <!--Restructuring Reserve-Biosciences [Member]-Termination benefits [Member]-->
  <us-gaap:RestructuringReserve contextRef="c20130630_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">454000</us-gaap:RestructuringReserve>
  <!--Restructuring Reserve-Contract termination costs [Member]-Biosciences [Member]-->
  <us-gaap:RestructuringReserve contextRef="c20130630_RestructuringCostAndReserveAxis_ContractTerminationMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">0</us-gaap:RestructuringReserve>
  <!--Restructuring Reserve-Biosciences [Member]-Other costs [Member]-->
  <us-gaap:RestructuringReserve contextRef="c20130630_RestructuringCostAndReserveAxis_OtherRestructuringMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">0</us-gaap:RestructuringReserve>
  <!--Restructuring Reserve-Biosciences [Member]-->
  <us-gaap:RestructuringReserve contextRef="c20130630_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">454000</us-gaap:RestructuringReserve>
  <!--Restructuring and Related Cost, Incurred Cost-Biosciences [Member]-Termination benefits [Member]-->
  <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c20130401to20130630_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">274000</us-gaap:RestructuringAndRelatedCostIncurredCost>
  <!--Restructuring and Related Cost, Incurred Cost-Contract termination costs [Member]-Biosciences [Member]-->
  <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c20130401to20130630_RestructuringCostAndReserveAxis_ContractTerminationMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">431000</us-gaap:RestructuringAndRelatedCostIncurredCost>
  <!--Restructuring and Related Cost, Incurred Cost-Biosciences [Member]-Other costs [Member]-->
  <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c20130401to20130630_RestructuringCostAndReserveAxis_OtherRestructuringMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">80000</us-gaap:RestructuringAndRelatedCostIncurredCost>
  <!--Restructuring and Related Cost, Incurred Cost-Biosciences [Member]-->
  <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c20130401to20130630_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">785000</us-gaap:RestructuringAndRelatedCostIncurredCost>
  <!--Restructuring and Related Activities Disclosure [Text Block]-->
  <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt; vertical-align: top; font-weight: bold; align: right;"&gt;8.&lt;/td&gt;&lt;td style="width: auto; font-family: 'Times New Roman', serif; font-size: 9pt; vertical-align: top; font-weight: bold;"&gt;Restructuring&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;In February 2013, the Company adopted a plan to restructure the operations of Emergent Product Development UK Limited ("EPDU") and OETC due to the results of the Phase IIb clinical trial for the Company's tuberculosis product candidate. &amp;#160;The Company has substantially completed this restructuring as of June 30, 2013.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Severance and other related costs and asset-related charges are reflected within the Company's consolidated statement of operations as a component of selling, general and administrative expense.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The restructuring plan includes a headcount reduction of 14 employees at EPDU, the termination of a facility lease, and the impairment of leasehold improvements and equipment. These costs, which are included in selling, general and administrative expense in its statement of operations and is included within the Biosciences segment, are detailed below:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Incurred during&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Incurred during&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;the three months&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;the six months&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Total Expected&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;ended June 30, 2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;ended June 30, 2013&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;to be Incurred&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Termination &amp;#160;benefits&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;274&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,114&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,114&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Contract termination &amp;#160;costs&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;431&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;431&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;431&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Other costs&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;80&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;261&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;261&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 64%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;785&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,806&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,806&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The following is a summary of the activity for the liabilities related to the EPDU restructuring:&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Contract&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Termination&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Termination&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Other&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Benefits&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Costs&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Costs&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Balance at December 31, 2012&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Expenses incurred&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,114&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;431&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;134&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,679&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Amount paid&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(1,660&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(431&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(134&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(2,225&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Other adjustments&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 52%; vertical-align: bottom;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Balance at June 30, 2013&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;454&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;454&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
  <!--Other adjustments-Biosciences [Member]-Termination benefits [Member]-->
  <us-gaap:RestructuringReserveTranslationAndOtherAdjustment contextRef="c20130101to20130630_RestructuringCostAndReserveAxis_SpecialTerminationBenefitsMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">0</us-gaap:RestructuringReserveTranslationAndOtherAdjustment>
  <!--Other adjustments-Contract termination costs [Member]-Biosciences [Member]-->
  <us-gaap:RestructuringReserveTranslationAndOtherAdjustment contextRef="c20130101to20130630_RestructuringCostAndReserveAxis_ContractTerminationMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">0</us-gaap:RestructuringReserveTranslationAndOtherAdjustment>
  <!--Other adjustments-Biosciences [Member]-Other costs [Member]-->
  <us-gaap:RestructuringReserveTranslationAndOtherAdjustment contextRef="c20130101to20130630_RestructuringCostAndReserveAxis_OtherRestructuringMember_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">0</us-gaap:RestructuringReserveTranslationAndOtherAdjustment>
  <!--Other adjustments-Biosciences [Member]-->
  <us-gaap:RestructuringReserveTranslationAndOtherAdjustment contextRef="c20130101to20130630_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">0</us-gaap:RestructuringReserveTranslationAndOtherAdjustment>
  <!--Retained earnings-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20130630" unitRef="U002" decimals="-3">222814000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Retained earnings-->
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c20121231" unitRef="U002" decimals="-3">220393000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <!--Revenues related to collaborative research funding-Abbott Laboratories TRU016 [Member]-->
  <us-gaap:RevenueFromGrants contextRef="c20120401to20120630_TypeOfArrangementAxis_AbbottLaboratoriesTru016Member" unitRef="U002" decimals="-5">1400000</us-gaap:RevenueFromGrants>
  <!--Revenues related to collaborative research funding-Abbott Laboratories TRU016 [Member]-->
  <us-gaap:RevenueFromGrants contextRef="c20120101to20120630_TypeOfArrangementAxis_AbbottLaboratoriesTru016Member" unitRef="U002" decimals="-5">2700000</us-gaap:RevenueFromGrants>
  <!--Revenues related to collaborative research funding-Pfizer CD20 [Member]-->
  <us-gaap:RevenueFromGrants contextRef="c20120401to20120630_TypeOfArrangementAxis_PfizerCd20Member" unitRef="U002" decimals="0">512000</us-gaap:RevenueFromGrants>
  <!--Revenues related to collaborative research funding-Pfizer CD20 [Member]-->
  <us-gaap:RevenueFromGrants contextRef="c20120101to20120630_TypeOfArrangementAxis_PfizerCd20Member" unitRef="U002" decimals="0">877000</us-gaap:RevenueFromGrants>
  <!--Revenue recognition-->
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left; text-indent: 18pt; font-family: 'Times New Roman', serif; margin-left: 18pt; font-size: 9pt; font-weight: bold;"&gt;Revenue recognition&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;There have been no significant changes to the Company's summary of significant accounting policies, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the SEC, during the three and six months ended June 30, 2013, except for the addition of the Company's policy for multiple element revenue-generating arrangements and its revenue recognition policy related to the Company's contract with the Biomedical Advanced Research and Development Authority ("BARDA") to establish a Center for Innovation in Advanced Development and Manufacturing ("CIADM").&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The Company analyzes its multiple element revenue-generating arrangements to determine whether the elements can be separated and accounted for individually as separate units of accounting. An item can generally be considered a separate unit of accounting if both of the following criteria are met: the delivered item(s) has value to the customer on a stand-alone basis and if the arrangement includes a general right of return and delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on the unit's selling price and is recognized in full when the criteria are met. The Company deems services to be rendered if no continuing obligation exists on the part of the Company.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The Company's contract with the BARDA to establish a CIADM is a service arrangement that includes multiple elements. The CIADM contract requires the Company to provide a flexible infrastructure to supply medical countermeasures to the U.S. Government over the contract period and includes such items as construction and facility design, workforce development and licensure of a pandemic flu vaccine. Since none of the individual elements by themselves satisfy the purpose of the contract, the Company has concluded that the CIADM contract elements cannot be separated as they do not have stand-alone value to the U.S. Government. Therefore, the Company has concluded that there is a single unit of account associated with the CIADM contract. The Company recognizes revenue under the CIADM contract on a straight-line basis, based upon its estimate of the total payments to be received under the contract. The Company analyzes the estimated payments to be received on a quarterly basis to determine if an adjustment to revenue is required. Changes in estimates attributed to modifications in the estimate of total payments to be received are recorded prospectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <!--External revenue-Biodefense [Member]-->
  <us-gaap:Revenues contextRef="c20130401to20130630_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U002" decimals="-3">82402000</us-gaap:Revenues>
  <!--External revenue-Biosciences [Member]-->
  <us-gaap:Revenues contextRef="c20130401to20130630_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">34000</us-gaap:Revenues>
  <!--External revenue-All Other [Member]-->
  <us-gaap:Revenues contextRef="c20130401to20130630_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U002" decimals="-3">0</us-gaap:Revenues>
  <!--External revenue-->
  <us-gaap:Revenues contextRef="c20130401to20130630" unitRef="U002" decimals="-3">82436000</us-gaap:Revenues>
  <!--External revenue-Biodefense [Member]-->
  <us-gaap:Revenues contextRef="c20120401to20120630_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U002" decimals="-3">66964000</us-gaap:Revenues>
  <!--External revenue-Biosciences [Member]-->
  <us-gaap:Revenues contextRef="c20120401to20120630_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">3415000</us-gaap:Revenues>
  <!--External revenue-All Other [Member]-->
  <us-gaap:Revenues contextRef="c20120401to20120630_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U002" decimals="-3">0</us-gaap:Revenues>
  <!--External revenue-->
  <us-gaap:Revenues contextRef="c20120401to20120630" unitRef="U002" decimals="-3">70379000</us-gaap:Revenues>
  <!--External revenue-Biodefense [Member]-->
  <us-gaap:Revenues contextRef="c20130101to20130630_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U002" decimals="-3">124561000</us-gaap:Revenues>
  <!--External revenue-Biosciences [Member]-->
  <us-gaap:Revenues contextRef="c20130101to20130630_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">975000</us-gaap:Revenues>
  <!--External revenue-All Other [Member]-->
  <us-gaap:Revenues contextRef="c20130101to20130630_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U002" decimals="-3">0</us-gaap:Revenues>
  <!--External revenue-->
  <us-gaap:Revenues contextRef="c20130101to20130630" unitRef="U002" decimals="-3">125536000</us-gaap:Revenues>
  <!--External revenue-Biodefense [Member]-->
  <us-gaap:Revenues contextRef="c20120101to20120630_StatementBusinessSegmentsAxis_BiodefenseMember" unitRef="U002" decimals="-3">115600000</us-gaap:Revenues>
  <!--External revenue-Biosciences [Member]-->
  <us-gaap:Revenues contextRef="c20120101to20120630_StatementBusinessSegmentsAxis_BiosciencesMember" unitRef="U002" decimals="-3">5090000</us-gaap:Revenues>
  <!--External revenue-All Other [Member]-->
  <us-gaap:Revenues contextRef="c20120101to20120630_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="U002" decimals="-3">0</us-gaap:Revenues>
  <!--External revenue-->
  <us-gaap:Revenues contextRef="c20120101to20120630" unitRef="U002" decimals="-3">120690000</us-gaap:Revenues>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value-Stock Options [Member]-->
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c20130630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0">3027603</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <!--Product sales-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c20130401to20130630" unitRef="U002" decimals="-3">65596000</us-gaap:SalesRevenueGoodsNet>
  <!--Product sales-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c20120401to20120630" unitRef="U002" decimals="-3">53161000</us-gaap:SalesRevenueGoodsNet>
  <!--Product sales-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c20130101to20130630" unitRef="U002" decimals="-3">95955000</us-gaap:SalesRevenueGoodsNet>
  <!--Product sales-->
  <us-gaap:SalesRevenueGoodsNet contextRef="c20120101to20120630" unitRef="U002" decimals="-3">87518000</us-gaap:SalesRevenueGoodsNet>
  <!--Revenue, Net-->
  <us-gaap:SalesRevenueNet contextRef="c20130401to20130630" unitRef="U002" decimals="-3">82436000</us-gaap:SalesRevenueNet>
  <!--Revenue, Net-->
  <us-gaap:SalesRevenueNet contextRef="c20120401to20120630" unitRef="U002" decimals="-3">70379000</us-gaap:SalesRevenueNet>
  <!--Revenue, Net-->
  <us-gaap:SalesRevenueNet contextRef="c20130101to20130630" unitRef="U002" decimals="-3">125536000</us-gaap:SalesRevenueNet>
  <!--Revenue, Net-->
  <us-gaap:SalesRevenueNet contextRef="c20120101to20120630" unitRef="U002" decimals="-3">120690000</us-gaap:SalesRevenueNet>
  <!--Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis-->
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: top;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;At June 30, 2013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Level 1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Level 2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Level 3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Investment in money market funds (1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,323&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,323&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Total assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,323&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,323&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: top;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;At December 31, 2012&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Level 1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Level 2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Level 3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Investment in money market funds (1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;42,720&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;42,720&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Total assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;42,720&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;42,720&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 54pt; vertical-align: top; align: right;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; color: #000000; margin-left: 36pt; font-size: 9pt;"&gt;(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="width: auto; vertical-align: top;"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', serif; color: #000000; font-size: 9pt;"&gt;Included in cash and cash equivalents in accompanying consolidated balance sheets.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <!--Option award activity-->
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The following is a summary of stock option award activity under the Second Amended and Restated Emergent BioSolutions Inc., 2006 Stock Incentive Plan (the "2006 Plan") and the Emergent BioSolutions Employee Stock Option Plan (the "2004 Plan"):&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;2006 Plan&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;2004 Plan&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Weighted-Average Exercise Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Weighted-Average Exercise Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Aggregate Intrinsic Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 40%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Outstanding at December 31, 2012&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;3,550,842&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;17.07&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;53,156&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;8.86&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;4,801,378&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 40%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;878,860&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;14.63&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 40%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(66,999&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;8.74&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 40%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(244,704&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;17.96&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 40%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Outstanding at June 30, 2013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;4,117,999&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;16.64&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;53,156&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;8.86&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;3,043,711&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 40%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Exercisable at June 30, 2013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,595,007&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;16.90&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;53,156&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;8.86&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;3,027,603&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <!--Schedule of Inventory, Current [Table Text Block]-->
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Inventories consist of the following:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;June 30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;2012&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Raw materials and supplies&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,613&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,733&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 76%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Work-in-process&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;10,960&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;9,813&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 76%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Finished goods&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;5,009&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,615&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 76%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Total inventories&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;18,582&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;15,161&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <!--Restricted stock units activity-->
  <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The following is a summary of restricted stock unit award activity under the 2006 Plan:&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Weighted-Average Grant Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Aggregate Intrinsic Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Outstanding at December 31, 2012&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;715,609&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;18.41&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;11,478,368&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;439,429&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;14.63&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(321,508&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;14.72&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(64,323&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;15.79&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Outstanding at June 30, 2013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;769,207&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;16.26&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;11,091,965&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
  <!--Summary of basic and diluted net income per share-->
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The following table presents the calculation of basic and diluted net income per share:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Three Months Ended June 30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Six Months Ended June 30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;(in thousands, except share and per share data)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;2012&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;2013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;2012&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Net income&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;10,484&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;7,632&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,422&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;800&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Weighted-average number of shares&amp;#8212;basic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,144,063&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,182,826&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,056,297&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,114,400&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Dilutive securities&amp;#8212;equity awards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;382,951&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;373,871&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;191,476&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;186,935&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Weighted-average number of shares&amp;#8212;diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,527,014&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,556,697&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,247,773&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;36,301,335&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Income per share-basic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;0.29&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;0.21&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;0.07&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;0.02&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Income per share-diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;0.29&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;0.21&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;0.07&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;0.02&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <!--Costs of the restructuring-->
  <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The restructuring plan includes a headcount reduction of 14 employees at EPDU, the termination of a facility lease, and the impairment of leasehold improvements and equipment. These costs, which are included in selling, general and administrative expense in its statement of operations and is included within the Biosciences segment, are detailed below:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Incurred during&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Incurred during&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;the three months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;the six months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Total Expected&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;ended June 30, 2013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;ended June 30, 2013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;to be Incurred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Termination &amp;#160;benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;274&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,114&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,114&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Contract termination &amp;#160;costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;431&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;431&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;431&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Other costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;80&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;261&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;261&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;785&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,806&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,806&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
  <!--Summary of the activity for liabilities related to EPDU restructuring-->
  <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The following is a summary of the activity for the liabilities related to the EPDU restructuring:&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: top;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Contract&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Termination&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Termination&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Balance at December 31, 2012&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Expenses incurred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,114&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;431&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;134&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,679&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Amount paid&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(1,660&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(431&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(134&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(2,225&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Other adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Balance at June 30, 2013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;454&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;454&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
  <!--Schedule of Variable Interest Entities [Table Text Block]-->
  <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The following is a summary of the stockholders' equity attributable to the Company and the noncontrolling interests:&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Emergent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Noncontrolling&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;BioSolutions Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Interests&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Stockholders' equity at December 31, 2012&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;441,358&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;770&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;442,128&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Non-cash development expenses from variable interest entities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(347&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(347&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,422&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(871&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;1,551&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;5,750&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;5,750&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Stockholders' equity at June 30, 2013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;449,530&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(448&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;449,082&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
  <!--Segment Reporting Disclosure [Text Block]-->
  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt; vertical-align: top; font-weight: bold; align: right;"&gt;11.&lt;/td&gt;&lt;td style="width: auto; font-family: 'Times New Roman', serif; font-size: 9pt; vertical-align: top; font-weight: bold;"&gt;Segment information&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;For financial reporting purposes, the Company reports financial information for two business segments: Biodefense and Biosciences. The Company's two business segments, or operating divisions, engage in business activities for which discrete financial information is reviewed by the chief operating decision maker. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company's reportable segments are composed of business units that offer different products and product candidates and are managed separately because they manufacture and develop distinct products and product candidates with different development processes.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The Biodefense division &lt;font style="background-color: #ffffff; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;is directed to government-sponsored development and supply of countermeasures against potential agents of bioterror or biowarfare and targets the infectious disease anthrax.&lt;/font&gt; Revenues in this segment are primarily from sales of the Company's FDA-licensed product, BioThrax&amp;#174; (Anthrax Vaccine Adsorbed), to the U.S. government. The Biosciences division &lt;font style="background-color: #ffffff; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;is directed to commercial opportunities and primarily targets oncology indications&lt;/font&gt;, and consists of two business units, therapeutics and vaccines. The "All Other" segment relates to the general operating costs of the Company and includes costs of the centralized services departments, which are not allocated to the other segments, as well as spending on activities that are not classified as Biodefense or Biosciences.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Reportable Segments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 20px;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Biodefense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Biosciences&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;All Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Three Months Ended June 30, 2013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;External revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;82,402&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;34&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;82,436&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;24,996&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(14,156&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(356&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;10,484&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Three Months Ended June 30, 2012&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;External revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;66,964&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;3,415&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;70,379&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;24,335&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(14,963&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(1,740&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;7,632&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Reportable Segments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Biodefense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Biosciences&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;All Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Six Months Ended June 30, 2013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;External revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;124,561&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;975&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;125,536&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;29,606&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(25,528&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(1,656&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,422&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Six Months Ended June 30, 2012&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;External revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;115,600&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;5,090&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;120,690&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 52%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;38,601&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(34,854&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(2,947&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;800&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <!--Selling, General and Administrative Expense-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c20130401to20130630" unitRef="U002" decimals="-3">20501000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Selling, General and Administrative Expense-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c20120401to20120630" unitRef="U002" decimals="-3">17895000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Selling, General and Administrative Expense-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c20130101to20130630" unitRef="U002" decimals="-3">40529000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Selling, General and Administrative Expense-->
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c20120101to20120630" unitRef="U002" decimals="-3">37387000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <!--Granted (in shares)-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c20130101to20130630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0">439429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c20130101to20130630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2">14.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <!--Granted (in dollars per share)-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c20130101to20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">14.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c20121231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0">715609</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c20130630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0">769207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c20130101to20130630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0">321508</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <!--Stock-based compensation expense-->
  <us-gaap:ShareBasedCompensation contextRef="c20130101to20130630" unitRef="U002" decimals="-3">5718000</us-gaap:ShareBasedCompensation>
  <!--Stock-based compensation expense-->
  <us-gaap:ShareBasedCompensation contextRef="c20120101to20120630" unitRef="U002" decimals="-3">5425000</us-gaap:ShareBasedCompensation>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c20121231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2">18.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c20130630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2">16.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="c20130101to20130630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2">15.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="c20130101to20130630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0">64323</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <!--Exercised (in dollars per share)-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c20130101to20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">8.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c20130101to20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="0">878860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c20130101to20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U001" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">16.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U003" decimals="2">8.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value-Restricted Stock Units (RSUs) [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="c20130101to20130630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2">14.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="0">2595007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U001" decimals="0">53156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <!--Forfeited (in dollars per share)-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c20130101to20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">17.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c20130101to20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="0">244704</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c20130101to20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U001" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20121231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">17.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20121231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U003" decimals="2">8.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U003" decimals="2">16.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U003" decimals="2">8.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20121231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="0">3550842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20121231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U001" decimals="0">53156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="0">4117999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U001" decimals="0">53156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c20121231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0">4801378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value-Stock Options [Member]-->
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c20130630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0">3043711</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <!--Significant Accounting Policies [Text Block]-->
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;font style="font-family: 'Times New Roman', serif; color: #000000; font-size: 9pt; font-weight: bold;"&gt;1.&lt;/font&gt;&lt;font style="font-size: 5.14pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', serif; color: #000000; font-size: 9pt; font-weight: bold;"&gt;Summary of significant accounting policies&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Basis of presentation and consolidation&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The accompanying unaudited consolidated financial statements include the accounts of Emergent BioSolutions Inc. (the "Company" or "Emergent") and its wholly-owned and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The unaudited consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission ("SEC").&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;In the opinion of the Company's management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of June 30, 2013 and the results of operations, comprehensive income and cash flows for the three and six months ended June 30, 2013 and 2012. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 18pt; font-family: 'Times New Roman', serif; margin-left: 18pt; font-size: 9pt; font-weight: bold;"&gt;Revenue recognition&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;There have been no significant changes to the Company's summary of significant accounting policies, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the SEC, during the three and six months ended June 30, 2013, except for the addition of the Company's policy for multiple element revenue-generating arrangements and its revenue recognition policy related to the Company's contract with the Biomedical Advanced Research and Development Authority ("BARDA") to establish a Center for Innovation in Advanced Development and Manufacturing ("CIADM").&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The Company analyzes its multiple element revenue-generating arrangements to determine whether the elements can be separated and accounted for individually as separate units of accounting. An item can generally be considered a separate unit of accounting if both of the following criteria are met: the delivered item(s) has value to the customer on a stand-alone basis and if the arrangement includes a general right of return and delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on the unit's selling price and is recognized in full when the criteria are met. The Company deems services to be rendered if no continuing obligation exists on the part of the Company.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The Company's contract with the BARDA to establish a CIADM is a service arrangement that includes multiple elements. The CIADM contract requires the Company to provide a flexible infrastructure to supply medical countermeasures to the U.S. Government over the contract period and includes such items as construction and facility design, workforce development and licensure of a pandemic flu vaccine. Since none of the individual elements by themselves satisfy the purpose of the contract, the Company has concluded that the CIADM contract elements cannot be separated as they do not have stand-alone value to the U.S. Government. Therefore, the Company has concluded that there is a single unit of account associated with the CIADM contract. The Company recognizes revenue under the CIADM contract on a straight-line basis, based upon its estimate of the total payments to be received under the contract. The Company analyzes the estimated payments to be received on a quarterly basis to determine if an adjustment to revenue is required. Changes in estimates attributed to modifications in the estimate of total payments to be received are recorded prospectively.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period-Stock Options [Member]-Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20130101to20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsInc2006StockIncentivePlanMember" unitRef="U001" decimals="0">66999</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period-Emergent BioSolutions Employee Stock Option Plan [Member]-Stock Options [Member]-->
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c20130101to20130630_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EmergentBiosolutionsEmployeeStockOptionPlanMember" unitRef="U001" decimals="0">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <!--Stockholders' Equity, Other-Emergent BioSolutions Inc. [Member]-->
  <us-gaap:StockholdersEquityOther contextRef="c20130101to20130630_StatementEquityComponentsAxis_ParentMember" unitRef="U002" decimals="-3">5750000</us-gaap:StockholdersEquityOther>
  <!--Stockholders' Equity, Other-Noncontrolling Interests [Member]-->
  <us-gaap:StockholdersEquityOther contextRef="c20130101to20130630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3">0</us-gaap:StockholdersEquityOther>
  <!--Stockholders' Equity, Other-->
  <us-gaap:StockholdersEquityOther contextRef="c20130101to20130630" unitRef="U002" decimals="-3">5750000</us-gaap:StockholdersEquityOther>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20130630" unitRef="U002" decimals="-3">449530000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity Attributable to Parent-->
  <us-gaap:StockholdersEquity contextRef="c20121231" unitRef="U002" decimals="-3">441358000</us-gaap:StockholdersEquity>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20130630" unitRef="U002" decimals="-3">449082000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20121231" unitRef="U002" decimals="-3">442128000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Emergent BioSolutions Inc. [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20121231_StatementEquityComponentsAxis_ParentMember" unitRef="U002" decimals="-3">441358000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Noncontrolling Interests [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20121231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3">770000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Emergent BioSolutions Inc. [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20130630_StatementEquityComponentsAxis_ParentMember" unitRef="U002" decimals="-3">449530000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest-Noncontrolling Interests [Member]-->
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c20130630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3">-448000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <!--Stockholders' equity-->
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div&gt;&lt;font style="font-family: 'Times New Roman', serif; color: #000000; font-size: 9pt; font-weight: bold;"&gt;5.&lt;/font&gt;&lt;font style="font-size: 5.14pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', serif; color: #000000; font-size: 9pt; font-weight: bold;"&gt;Equity awards&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The following is a summary of stock option award activity under the Second Amended and Restated Emergent BioSolutions Inc., 2006 Stock Incentive Plan (the "2006 Plan") and the Emergent BioSolutions Employee Stock Option Plan (the "2004 Plan"):&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;2006 Plan&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;2004 Plan&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Weighted-Average Exercise Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Weighted-Average Exercise Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Aggregate Intrinsic Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 40%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Outstanding at December 31, 2012&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;3,550,842&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;17.07&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;53,156&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;8.86&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;4,801,378&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 40%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;878,860&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;14.63&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 40%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(66,999&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;8.74&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 40%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(244,704&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;17.96&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; padding-bottom: 2px; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 40%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Outstanding at June 30, 2013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;4,117,999&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;16.64&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;53,156&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;8.86&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;3,043,711&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 40%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Exercisable at June 30, 2013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;2,595,007&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;16.90&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;53,156&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;8.86&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;3,027,603&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;The following is a summary of restricted stock unit award activity under the 2006 Plan:&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Number of Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Weighted-Average Grant Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" valign="bottom" style="border-bottom: #000000 2px solid; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Aggregate Intrinsic Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Outstanding at December 31, 2012&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;715,609&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;18.41&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;11,478,368&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;439,429&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;14.63&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(321,508&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;14.72&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ffffff;"&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; text-indent: 9pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;(64,323&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;15.79&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 2px solid; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #cceeff;"&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 64%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;Outstanding at June 30, 2013&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;769,207&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;16.26&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: left; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: #000000 4px double; text-align: right; width: 9%; vertical-align: bottom;"&gt;&lt;div&gt;&lt;div style="font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;11,091,965&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px; width: 1%; vertical-align: bottom;"&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;During the six months ended June 30, 2013, the Company corrected an immaterial prior period classification error for the six months ended June 30, 2012 of approximately $2.6 million. This immaterial error related to the cash flow presentation of the excess tax benefit attributed to the exercise of non-qualified stock options and restricted stock units. The immaterial error had no impact on the Company's consolidated cash flows, consolidated statements of operations and comprehensive income or the consolidated balance sheets. The correction of the error is reflected as a reduction of originally reported operating cash flow from operating activities and an increase in originally reported cash flow from financing activities.&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <!--Subsequent Events [Text Block]-->
  <us-gaap:SubsequentEventsTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: left;"&gt;&lt;font style="font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;12.&lt;/font&gt;&lt;font style="font-size: 5.14pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'Times New Roman', serif; font-size: 9pt; font-weight: bold;"&gt;Subsequent events&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;On August 1, 2013, the Company acquired substantially all of the assets of the Healthcare Protective Products Division ("HPPD"), a division of Bracco Diagnostics Inc. for approximately $24.2 million in cash. The assets acquired in the August 2013 acquisition include HPPD's product RSDL&amp;#174;, (decontamination lotion) ("RSDL") along with all of the customer and distributor agreements for the RSDL product. In addition, as part of the acquisition, the Company will pay approximately $1.8 million for the remaining assets of HPPD, which primarily includes manufacturing equipment. The Company anticipates the acquisition of the remaining assets will occur during the fourth quarter of 2013. The acquisition will diversify the Biodefense segment by adding product sales from RSDL. The Company has incurred transaction costs related to the acquisition of approximately $387,000 and $515,000, respectively, for the three and six months ended June 30, 2013, which has been recorded in selling, general and administrative expenses within the Company's Biodefense segment. As of the date of this filing, the valuation of acquired tangible and identification of any intangible assets has not been completed as valuation specialists have not yet completed their assessment. &amp;#160;Therefore, the estimate of fair value of the acquired assets and any other fair value adjustments are not complete, and as such the purchase price allocation for the transaction has not been completed.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <!--Treasury Stock ( in Shares)-->
  <us-gaap:TreasuryStockShares contextRef="c20130630" unitRef="U001" decimals="0">403158</us-gaap:TreasuryStockShares>
  <!--Treasury Stock ( in Shares)-->
  <us-gaap:TreasuryStockShares contextRef="c20121231" unitRef="U001" decimals="0">403158</us-gaap:TreasuryStockShares>
  <!--Treasury Stock, Value-->
  <us-gaap:TreasuryStockValue contextRef="c20130630" unitRef="U002" decimals="-3">5906000</us-gaap:TreasuryStockValue>
  <!--Treasury Stock, Value-->
  <us-gaap:TreasuryStockValue contextRef="c20121231" unitRef="U002" decimals="-3">5906000</us-gaap:TreasuryStockValue>
  <!--Variable Interest Entity, Consolidated, Carrying Amount, Assets-Oxford Emergent Tuberculosis Consortium [Member]-->
  <us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets contextRef="c20130630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember" unitRef="U002" decimals="0">291000</us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets>
  <!--Variable Interest Entity, Consolidated, Carrying Amount, Assets-Oxford Emergent Tuberculosis Consortium [Member]-->
  <us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets contextRef="c20120630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember" unitRef="U002" decimals="-5">3500000</us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets>
  <!--Variable Interest Entity, Measure of Activity, Expense-Emergent BioSolutions Inc. [Member]-->
  <us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityExpense contextRef="c20130101to20130630_StatementEquityComponentsAxis_ParentMember" unitRef="U002" decimals="-3">0</us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityExpense>
  <!--Variable Interest Entity, Measure of Activity, Expense-Noncontrolling Interests [Member]-->
  <us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityExpense contextRef="c20130101to20130630_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U002" decimals="-3">-347000</us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityExpense>
  <!--Variable Interest Entity, Measure of Activity, Expense-->
  <us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityExpense contextRef="c20130101to20130630" unitRef="U002" decimals="-3">-347000</us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityExpense>
  <!--Variable Interest Entity, Consolidated, Carrying Amount, Liabilities-Oxford Emergent Tuberculosis Consortium [Member]-->
  <us-gaap:VariableInterestEntityConsolidatedCarryingAmountLiabilities contextRef="c20130630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember" unitRef="U002" decimals="0">229000</us-gaap:VariableInterestEntityConsolidatedCarryingAmountLiabilities>
  <!--Variable Interest Entity, Consolidated, Carrying Amount, Liabilities-Oxford Emergent Tuberculosis Consortium [Member]-->
  <us-gaap:VariableInterestEntityConsolidatedCarryingAmountLiabilities contextRef="c20120630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember" unitRef="U002" decimals="-5">1300000</us-gaap:VariableInterestEntityConsolidatedCarryingAmountLiabilities>
  <!--Ownership percentage of variable interest entity (in hundredths)-Oxford Emergent Tuberculosis Consortium [Member]-->
  <us-gaap:VariableInterestEntityOwnershipPercentage contextRef="c20130401to20130630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember" unitRef="U004" decimals="2">0.51</us-gaap:VariableInterestEntityOwnershipPercentage>
  <!--Net losses included in the Company's consolidated statement of operations-Oxford Emergent Tuberculosis Consortium [Member]-->
  <us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax contextRef="c20130401to20130630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember" unitRef="U002" decimals="0">133000</us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax>
  <!--Net losses included in the Company's consolidated statement of operations-Oxford Emergent Tuberculosis Consortium [Member]-->
  <us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax contextRef="c20130101to20130630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember" unitRef="U002" decimals="0">905000</us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax>
  <!--Net losses included in the Company's consolidated statement of operations-Oxford Emergent Tuberculosis Consortium [Member]-->
  <us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax contextRef="c20120401to20120630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember" unitRef="U002" decimals="-5">2100000</us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax>
  <!--Net losses included in the Company's consolidated statement of operations-Oxford Emergent Tuberculosis Consortium [Member]-->
  <us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax contextRef="c20120101to20120630_VariableInterestEntitiesByClassificationOfEntityAxis_OxfordEmergentTuberculosisConsortiumMember" unitRef="U002" decimals="-5">3300000</us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityIncomeOrLossBeforeTax>
  <!--Weighted-average number of shares - basic-->
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c20130401to20130630" unitRef="U001" decimals="0">36144063</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Weighted-average number of shares - basic-->
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c20120401to20120630" unitRef="U001" decimals="0">36182826</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Weighted-average number of shares - basic-->
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c20130101to20130630" unitRef="U001" decimals="0">36056297</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Weighted-average number of shares - basic-->
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c20120101to20120630" unitRef="U001" decimals="0">36114400</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Weighted-average number of shares - diluted-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20130401to20130630" unitRef="U001" decimals="0">36527014</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--Weighted-average number of shares - diluted-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20120401to20120630" unitRef="U001" decimals="0">36556697</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--Weighted-average number of shares - diluted-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20130101to20130630" unitRef="U001" decimals="0">36247773</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--Weighted-average number of shares - diluted-->
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c20120101to20120630" unitRef="U001" decimals="0">36301335</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <!--In process research and development-->
  <ebs:InProcessResearchAndDevelopment contextRef="c20130630" unitRef="U002" decimals="-3">41800000</ebs:InProcessResearchAndDevelopment>
  <!--In process research and development-->
  <ebs:InProcessResearchAndDevelopment contextRef="c20121231" unitRef="U002" decimals="-3">41800000</ebs:InProcessResearchAndDevelopment>
  <!--Provision For Fair Value Of Contingent Value Rights-->
  <ebs:ProvisionForFairValueOfContingentValueRights contextRef="c20130101to20130630" unitRef="U002" decimals="-3">0</ebs:ProvisionForFairValueOfContingentValueRights>
  <!--Provision For Fair Value Of Contingent Value Rights-->
  <ebs:ProvisionForFairValueOfContingentValueRights contextRef="c20120101to20120630" unitRef="U002" decimals="-3">-3005000</ebs:ProvisionForFairValueOfContingentValueRights>
  <!--Proceeds From Borrowings On Long Term Indebtness And Line Of Credit-->
  <ebs:ProceedsFromBorrowingsOnLongTermIndebtnessAndLineOfCredit contextRef="c20130101to20130630" unitRef="U002" decimals="-3">0</ebs:ProceedsFromBorrowingsOnLongTermIndebtnessAndLineOfCredit>
  <!--Proceeds From Borrowings On Long Term Indebtness And Line Of Credit-->
  <ebs:ProceedsFromBorrowingsOnLongTermIndebtnessAndLineOfCredit contextRef="c20120101to20120630" unitRef="U002" decimals="-3">11413000</ebs:ProceedsFromBorrowingsOnLongTermIndebtnessAndLineOfCredit>
  <!--Contingent value right payment-->
  <ebs:ContingentValueRightPayment contextRef="c20130101to20130630" unitRef="U002" decimals="-3">0</ebs:ContingentValueRightPayment>
  <!--Contingent value right payment-->
  <ebs:ContingentValueRightPayment contextRef="c20120101to20120630" unitRef="U002" decimals="-3">1748000</ebs:ContingentValueRightPayment>
  <!--Share Based Compensation Arrangement, Equity Instruments other than Options, Outstanding, Aggregate Intrinsic value-Restricted Stock Units (RSUs) [Member]-->
  <ebs:ShareBasedCompensationArrangementEquityInstrumentsOtherThanOptionsOutstandingAggregateIntrinsicValue contextRef="c20121231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0">11478368</ebs:ShareBasedCompensationArrangementEquityInstrumentsOtherThanOptionsOutstandingAggregateIntrinsicValue>
  <!--Share Based Compensation Arrangement, Equity Instruments other than Options, Outstanding, Aggregate Intrinsic value-Restricted Stock Units (RSUs) [Member]-->
  <ebs:ShareBasedCompensationArrangementEquityInstrumentsOtherThanOptionsOutstandingAggregateIntrinsicValue contextRef="c20130630_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0">11091965</ebs:ShareBasedCompensationArrangementEquityInstrumentsOtherThanOptionsOutstandingAggregateIntrinsicValue>
  <!--Business Interruption Insurance Recovery [Text Block]-->
  <ebs:BusinessInterruptionInsuranceRecoveryTextBlock contextRef="c20130101to20130630">&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;div style="text-align: justify;"&gt;&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;tr&gt;&lt;td style="width: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt; vertical-align: top; font-weight: bold; align: right;"&gt;9.&lt;/td&gt;&lt;td style="width: auto; font-family: 'Times New Roman', serif; font-size: 9pt; vertical-align: top; font-weight: bold;"&gt;Business interruption insurance recovery&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 9pt;"&gt;During the three and six months ended June 30, 2012, respectively, the Company recorded $843,000 and $1.7 million from an insurance recovery related to a power outage at its Lansing, Michigan facility. The insurance recovery is classified in the Company's statement of operations as other income (expense), net.&lt;/div&gt;&lt;/div&gt;</ebs:BusinessInterruptionInsuranceRecoveryTextBlock>
  <!--BusinessInterruptionInsuranceRevenue-->
  <ebs:Businessinterruptioninsurancerevenue contextRef="c20120401to20120630" unitRef="U002" decimals="0">843000</ebs:Businessinterruptioninsurancerevenue>
  <!--BusinessInterruptionInsuranceRevenue-->
  <ebs:Businessinterruptioninsurancerevenue contextRef="c20120101to20120630" unitRef="U002" decimals="-5">1700000</ebs:Businessinterruptioninsurancerevenue>
  <!--Number of business units-->
  <ebs:NumberOfBusinessUnits contextRef="c20130101to20130630" unitRef="U004" decimals="INF">2</ebs:NumberOfBusinessUnits>
  <!--Transaction costs related to acquisition-Healthcare Protective Products Divisions [Member]-->
  <ebs:TransactionCostsRelatedToAcquisition contextRef="c20130401to20130630_BusinessAcquisitionAxis_HealthcareProtectiveProductsDivisionsMember" unitRef="U002" decimals="0">387000</ebs:TransactionCostsRelatedToAcquisition>
  <!--Transaction costs related to acquisition-Healthcare Protective Products Divisions [Member]-->
  <ebs:TransactionCostsRelatedToAcquisition contextRef="c20130101to20130630_BusinessAcquisitionAxis_HealthcareProtectiveProductsDivisionsMember" unitRef="U002" decimals="0">515000</ebs:TransactionCostsRelatedToAcquisition>
</xbrl>
